Hypoxia-inducible factors in human pulmonary arterial hypertension: A link to the intrinsic myeloid abnormalities

Blood

Volumn 117, Issue 13, 2011, Pages 3485-3493

  Farha, Samar ^a   Asosingh, Kewal ^a   Xu, Weiling ^a   Sharp, Jacqueline ^a   George, Deepa ^a   Comhair, Suzy ^a   Park, Margaret ^a   Tang, W H Wilson ^a   Loyd, James E ^b   Theil, Karl ^a   Tubbs, Raymond ^a   Hsi, Eric ^a   Lichtin, Alan ^c   Erzurum, Serpil C ^a  

^a LERNER RESEARCH INSTITUTE   (United States)

^b VANDERBILT UNIVERSITY   (United States)

^c TAUSSIG CANCER INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ERYTHROPOIETIN; HYPOXIA INDUCIBLE FACTOR; RETICULIN; SCATTER FACTOR; STEM CELL FACTOR;

ARTICLE; BONE MARROW; CASE REPORT; CELL LINEAGE; CONTROLLED STUDY; ENDOTHELIUM CELL; ERYTHROID CELL; FAMILIAL DISEASE; FAMILY; FEMALE; HUMAN; HUMAN CELL; HUMAN TISSUE; LUNG BLOOD VESSEL; LUNG ENDOTHELIUM; LUNG FIBROSIS; MALE; MYELOPROLIFERATIVE DISORDER; PRIORITY JOURNAL; PULMONARY ARTERY; PULMONARY HYPERTENSION; STEM CELL;

EID: 79953648058     PISSN: 00064971     EISSN: 15280020     Source Type: Journal    
DOI: 10.1182/blood-2010-09-306357     Document Type: Article

References (52)

1. Masri FA, Xu W, Comhair SA, et al. Hyperproliferative apoptosis-resistant endothelial cells in idiopathic pulmonary arterial hypertension. Am J Physiol Lung Cell Mol Physiol. 2007;293(3):L548-L554. (Pubitemid 47358814)
2. Tuder RM, Chacon M, Alger L, et al. Expression of angiogenesis-related molecules in plexiform lesions in severe pulmonary hypertension: evidence for a process of disordered angiogenesis. J Pathol. 2001;195(3):367-374.
3. Xu W, Koeck T, Lara AR, et al. Alterations of cellular bioenergetics in pulmonary artery endothelial cells. Proc Natl Acad Sci U S A. 2007;104(4):1342-1347. (Pubitemid 46184006)
4. Risau W, Sariola H, Zerwes HG, et al. Vasculogenesis and angiogenesis in embryonic-stem-cell-derived embryoid bodies. Development. 1988;102(3):471-478. (Pubitemid 18084930)
5. Risau W, Flamme I. Vasculogenesis. Annu Rev Cell Dev Biol. 1995;11:73-91. (Pubitemid 26019602)
6. Ribatti D, Vacca A, Roncali L, Dammacco F. Hematopoiesis and angiogenesis: a link between two apparently independent processes. J Hematother Stem Cell Res. 2000;9(1):13-19. (Pubitemid 30159497)
7. Choi K, Kennedy M, Kazarov A, Papadimitriou JC, Keller G. A common precursor for hematopoietic and endothelial cells. Development. 1998;125(4):725-732. (Pubitemid 28108096)
8. Loges S, Fehse B, Brockmann MA, et al. Identification of the adult human hemangioblast. Stem Cells Dev. 2004;13(3):229-242. (Pubitemid 38738365)
9. Yoder MC, Ingram DA. Endothelial progenitor cell: ongoing controversy for defining these cells and their role in neoangiogenesis in the murine system. Curr Opin Hematol. 2009;16(4):269-273.
10. Yoder MC. Defining human endothelial progenitor cells. J Thromb Haemost. 2009;7(suppl 1):49-52.
11. Lyden D, Hattori K, Dias S, et al. Impaired recruitment of bone-marrow-derived endothelial and hematopoietic precursor cells blocks tumor angiogenesis and growth. Nat Med. 2001;7(11): 1194-1201. (Pubitemid 33063774)
12. Prater DN, Case J, Ingram DA, Yoder MC. Working hypothesis to redefine endothelial progenitor cells. Leukemia. 2007;21(6):1141-1149. (Pubitemid 46831802)
13. Asahara T, Murohara T, Sullivan A, et al. Isolation of putative progenitor endothelial cells for angiogenesis. Science. 1997;275(5302):964-967. (Pubitemid 27087709)
14. Shojaei F, Wu X, Zhong C, et al. Bv8 regulates myeloid-cell-dependent tumour angiogenesis. Nature. 2007;450(7171):825-831. (Pubitemid 350231321)
15. Takakura N, Watanabe T, Suenobu S, et al. A role for hematopoietic stem cells in promoting angiogenesis. Cell. 2000;102(2):199-209.
16. Grunewald M, Avraham I, Dor Y, et al. VEGF-induced adult neovascularization: recruitment, retention, and role of accessory cells. Cell. 2006; 124(1):175-189. (Pubitemid 43069318)
17. Murdoch C, Muthana M, Coffelt SB, Lewis CE. The role of myeloid cells in the promotion of tumour angiogenesis. Nat Rev Cancer. 2008;8(8):618-631.
18. Joyce JA, Pollard JW. Microenvironmental regulation of metastasis. Nat Rev Cancer. 2009;9(4): 239-252.
19. Toshner M, Voswinckel R, Southwood M, et al. Evidence of dysfunction of endothelial progenitors in pulmonary arterial hypertension. Am J Respir Crit Care Med. 2009;180(8):780-787.
20. Asosingh K, Aldred MA, Vasanji A, et al. Circulating angiogenic precursors in idiopathic pulmonary arterial hypertension. Am J Pathol. 2008;172(3):615-627. (Pubitemid 351354535)
21. Pruijt JF, Willemze R, Fibbe WE. Mechanisms underlying hematopoietic stem cell mobilization induced by the CXC chemokine interleukin-8. Curr Opin Hematol. 1999;6(3):152-158. (Pubitemid 29467538)
22. Nor JE, Christensen J, Mooney DJ, Polverini PJ. Vascular endothelial growth factor (VEGF)-mediated angiogenesis is associated with enhanced endothelial cell survival and induction of Bcl-2 expression. Am J Pathol. 1999;154(2):375-384. (Pubitemid 29094088)
23. Asahara T, Takahashi T, Masuda H, et al. VEGF contributes to postnatal neovascularization by mobilizing bone marrow-derived endothelial progenitor cells. EMBO J. 1999;18(14):3964-3972. (Pubitemid 29335849)
24. Semenza GL. Targeting HIF-1 for cancer therapy. Nat Rev Cancer. 2003;3(10):721-732. (Pubitemid 37328811)
25. Morishita R, Nakamura S, Hayashi S, et al. Therapeutic angiogenesis induced by human recombinant hepatocyte growth factor in rabbit hind limb ischemia model as cytokine supplement therapy. Hypertension. 1999;33(6):1379-1384. (Pubitemid 29282658)
26. Carlini RG, Reyes AA, Rothstein M. Recombinant human erythropoietin stimulates angiogenesis in vitro. Kidney Int. 1995;47(3):740-745.
27. Weimar IS, Miranda N, Muller EJ, et al. Hepatocyte growth factor/scatter factor (HGF/SF) is produced by human bone marrow stromal cells and promotes proliferation, adhesion and survival of human hematopoietic progenitor cells (CD34+). Exp Hematol. 1998;26(9):885-894. (Pubitemid 28350760)
28. Grimm C, Wenzel A, Groszer M, et al. HIF-1-induced erythropoietin in the hypoxic retina protects against light-induced retinal degeneration. Nat Med. 2002;8(7):718-724. (Pubitemid 34778725)
29. Heeschen C, Aicher A, Lehmann R, et al. Erythropoietin is a potent physiologic stimulus for endothelial progenitor cell mobilization. Blood. 2003;102(4):1340-1346. (Pubitemid 36988041)
30. Hubel K, Engert A. Clinical applications of granulocyte colony-stimulating factor: an update and summary. Ann Hematol. 2003;82(4):207-213. (Pubitemid 36701010)
31. Ceradini DJ, Kulkarni AR, Callaghan MJ, et al. Progenitor cell trafficking is regulated by hypoxic gradients through HIF-1 induction of SDF-1. Nat Med. 2004;10(8):858-864. (Pubitemid 39070860)
32. Du R, Lu KV, Petritsch C, et al. HIF1alpha induces the recruitment of bone marrow-derived vascular modulatory cells to regulate tumor angiogenesis and invasion. Cancer Cell. 2008; 13(3):206-220. (Pubitemid 351318372)
33. Ieda Y, Fujita J, Ieda M, et al. G-CSF and HGF: combination of vasculogenesis and angiogenesis synergistically improves recovery in murine hind limb ischemia. J Mol Cell Cardiol. 2007;42(3):540-548. (Pubitemid 46349121)
34. Rafii S, Lyden D, Benezra R, Hattori K, Heissig B. Vascular and haematopoietic stem cells: novel targets for anti-angiogenesis therapy? Nat Rev Cancer. 2002;2(11):826-835. (Pubitemid 37328901)
35. Hill JM, Zalos G, Halcox JP, et al. Circulating endothelial progenitor cells, vascular function, and cardiovascular risk. N Engl J Med. 2003;348(7):593-600. (Pubitemid 36204953)
36. Bauermeister DE. Quantitation of bone marrow reticulin-a normal range. Am J Clin Pathol. 1971;56(1):24-31.
37. Murugesan G, Aboudola S, Szpurka H, et al. Identification of the JAK2 V617F mutation in chronic myeloproliferative disorders using FRET probes and melting curve analysis. Am J Clin Pathol. 2006;125(4):625-633.
38. Yoder MC, Mead LE, Prater D, et al. Redefining endothelial progenitor cells via clonal analysis and hematopoietic stem/progenitor cell principals. Blood. 2007;109(5):1801-1809. (Pubitemid 46348173)
39. Kralovics R, Passamonti F, Buser AS, et al. A gain-of-function mutation of JAK2 in myeloproliferative disorders. N Engl J Med. 2005;352(17):1779-1790. (Pubitemid 40570926)
40. Popat U, Frost A, Liu E, et al. High levels of circulating CD34 cells, dacrocytes, clonal hematopoiesis, and JAK2 mutation differentiate myelofibrosis with myeloid metaplasia from secondary myelofibrosis associated with pulmonary hypertension. Blood. 2006;107(9):3486-3488.
41. Beckman EN, Brown AW Jr. Normal reticulin level in iliac bone marrow. Arch Pathol Lab Med. 1990;114(12):1241-1243.
42. Popat U, Frost A, Liu E, et al. New onset of myelofibrosis in association with pulmonary arterial hypertension. Ann Intern Med. 2005;143(6):466-467. (Pubitemid 41338947)
43. Teofili L, Martini M, Cenci T, et al. Different STAT-3 and STAT-5 phosphorylation discriminates among Ph-negative chronic myeloproliferative diseases and is independent of the V617F JAK-2 mutation. Blood. 2007;110(1):354-359. (Pubitemid 47026854)
44. Majka SM, Skokan M, Wheeler L, et al. Evidence for cell fusion is absent in vascular lesions associated with pulmonary arterial hypertension. Am J Physiol Lung Cell Mol Physiol. 2008;295(6):L1028-L1039.
45. Fijalkowska I, Xu W, Comhair SA, et al. Hypoxia inducible-factor1alpha regulates the metabolic shift of pulmonary hypertensive endothelial cells. Am J Pathol. 2010;176(3):1130-1138.
46. Bonnet S, Michelakis ED, Porter CJ, et al. An abnormal mitochondrial-hypoxia inducible factor- 1alpha-Kv channel pathway disrupts oxygen sensing and triggers pulmonary arterial hypertension in fawn hooded rats: similarities to human pulmonary arterial hypertension. Circulation. 2006;113(22):2630-2641. (Pubitemid 43948012)
47. Krasuski RA, Hart SA, Smith B, Wang A, Harrison JK, Bashore TM. Association of anemia and longterm survival in patients with pulmonary hypertension [published online ahead of print May 14, 2010]. Int J Cardiol. doi:10.1016/j.ijcard.2010.04.038.
48. Smith TG, Talbot NP, Privat C, et al. Effects of iron supplementation and depletion on hypoxic pulmonary hypertension: two randomized controlled trials. JAMA. 2009;302:1444-1450.
49. Dingli D, Utz JP, Krowka MJ, Oberg AL, Tefferi A. Unexplained pulmonary hypertension in chronic myeloproliferative disorders. Chest. 2001;120(3):801-808. (Pubitemid 32885453)
50. Garypidou V, Vakalopoulou S, Dimitriadis D, Tziomalos K, Sfikas G, Perifanis V. Incidence of pulmonary hypertension in patients with chronic myeloproliferative disorders. Haematologica. 2004;89(2):245-246. (Pubitemid 38796505)
51. Rossoff LJ, Genovese J, Coleman M, Dantzker DR. Primary pulmonary hypertension in a patient with CD8/T-cell large granulocyte leukemia: amelioration by cladribine therapy. Chest. 1997;112(2):551-553. (Pubitemid 27349454)
52. Steensma DP, Hook CC, Stafford SL, Tefferi A. Low-dose, single-fraction, whole-lung radiotherapy for pulmonary hypertension associated with myelofibrosis with myeloid metaplasia. Br J Haematol. 2002;118(3):813-816. (Pubitemid 35007387)